Shares trade at one of the lowest earnings multiples among its peers. Most of the investment bank analysts who cover the ...

Shares of Bristol Myers Squibb Co. BMY advanced 1.17% to $48.46 Monday, on what proved to be an all-around positive trading ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Leading health technology company MentalHealth.com is pleased to announce its acquisition of online mental health resource ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

The analysis, conducted by Ernst & Young, found the United States imported $203 billion in pharmaceutical products in 2023, ...

Bristol-Myers Squibb raised its 2025 EPS outlook after a Q1 beat, with shares trading far below historical P/E levels. Find ...

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report).

Though 45% of patients said they could see the benefits of AI in health care, 44% said the idea of AI in health care settings scares them.